Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health

Show simple item record

dc.identifier.uri http://dx.doi.org/10.15488/3625
dc.identifier.uri https://www.repo.uni-hannover.de/handle/123456789/3657
dc.contributor.author Mühlberger, Nikolai
dc.contributor.author Sroczynski, Gaby
dc.contributor.author Esteban, Eva
dc.contributor.author Mittendorf, Thomas
dc.contributor.author Miksad, Rebecca A.
dc.contributor.author Siebert, Uwe
dc.date.accessioned 2018-08-23T12:59:40Z
dc.date.available 2018-08-23T12:59:40Z
dc.date.issued 2008
dc.identifier.citation Mühlberger, N.; Sroczynski, G.; Esteban, E.; Mittendorf, T.; Miksad, R.A.; Siebert, U.: Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. In: International Journal of Technology Assessment in Health Care 24 (2008), Nr. 2, S. 184-192. DOI: https://doi.org/10.1017/S0266462308080264
dc.description.abstract Objectives: The aim of this study was to summarize the current evidence for the cost-effectiveness of primarily human papillomavirus (HPV) -based cervical cancer screening in settings with already established Papanicolaou test (Pap) programs. Emphasis was placed on the German situation with annual Pap screening. Methods: Medical, economic, and health technology assessment (HTA) databases were systematically searched for cost-effectiveness studies comparing HPV to Pap screening. Study data were extracted, standardized, and summarized in cost-effectiveness plots contrasting HPV strategies to Pap screening with 1-, 2-, 3-, and 5-years interval. For each Pap setting, the likelihood of cost-effective HPV screening was assessed depending on willingness-to-pay. Results: We reviewed twelve decision-analytic cost-effectiveness models. Study results showed wide variation due to methodical heterogeneity. Data synthesis revealed that the cost-effectiveness of HPV screening depends on the interval of the established Pap screening strategy. In comparison with Pap screening every 2 years, only 25 percent of the HPV-based screening strategies were cost-effective. However, in comparison with Pap screening every 1, 3, or 5 years, 83 percent, 55 percent, and 92 percent of HPV screening strategies were cost-effective, respectively. Results for settings with annual Pap screening are based on models assuming 100 percent screening coverage. Conclusions: The introduction of HPV-based screening programs is cost-effective if the screening interval of the established Pap program exceeds 2 years. In settings with biennial Pap screening, introduction of HPV-based screening is unlikely to be cost-effective. Results also suggest cost-effectiveness of HPV-based screening in settings with annual Pap screening; however, this finding should be confirmed under realistic screening adherence assumptions. © 2008 Cambridge University Press. eng
dc.language.iso eng
dc.publisher Cambridge : Cambridge University Press
dc.relation.ispartofseries International Journal of Technology Assessment in Health Care 24 (2008), Nr. 2
dc.rights Es gilt deutsches Urheberrecht. Das Dokument darf zum eigenen Gebrauch kostenfrei genutzt, aber nicht im Internet bereitgestellt oder an Außenstehende weitergegeben werden. Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
dc.subject Cervical cancer eng
dc.subject Cost-effectiveness eng
dc.subject Health technology assessment eng
dc.subject Human papillomavirus eng
dc.subject Screening eng
dc.subject Cervical cancer eng
dc.subject Health technology assessment eng
dc.subject Human papillomavirus eng
dc.subject Cost effectiveness eng
dc.subject Medical problems eng
dc.subject Screening eng
dc.subject Health care eng
dc.subject biomedical technology assessment eng
dc.subject cancer screening eng
dc.subject cost effectiveness analysis eng
dc.subject diagnostic value eng
dc.subject female eng
dc.subject Germany eng
dc.subject health program eng
dc.subject human eng
dc.subject information processing eng
dc.subject intermethod comparison eng
dc.subject major clinical study eng
dc.subject Papanicolaou test eng
dc.subject patient compliance eng
dc.subject prospective payment eng
dc.subject review eng
dc.subject standardization eng
dc.subject systematic review eng
dc.subject uterine cervix cancer eng
dc.subject Wart virus eng
dc.subject Cost-Benefit Analysis eng
dc.subject Decision Support Techniques eng
dc.subject Female eng
dc.subject Germany eng
dc.subject Humans eng
dc.subject Mass Screening eng
dc.subject Papillomavirus Infections eng
dc.subject Quality-Adjusted Life Years eng
dc.subject Sensitivity and Specificity eng
dc.subject Technology Assessment, Biomedical eng
dc.subject Uterine Cervical Neoplasms eng
dc.subject Vaginal Smears eng
dc.subject.ddc 330 | Wirtschaft ger
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.title Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health
dc.type review
dc.type Text
dc.relation.issn 02664623
dc.relation.doi https://doi.org/10.1017/S0266462308080264
dc.bibliographicCitation.issue 2
dc.bibliographicCitation.volume 24
dc.bibliographicCitation.firstPage 184
dc.bibliographicCitation.lastPage 192
dc.description.version publishedVersion
tib.accessRights frei zug�nglich


Files in this item

This item appears in the following Collection(s):

Show simple item record

 

Search the repository


Browse

My Account

Usage Statistics